Christopher Nevala-Plagemann,
MD
No Rating Available?
0
out of
5
Patient Rating
In order to provide our patients and visitors with the most accurate and useful information, we only post physician satisfaction data when a physician has received a minimum of 30 returned surveys. For this provider, we have not yet received the
minimum.
Languages Spoken: English
Clinical Locations
Clinic 2B, GI Oncology
801-585-0250
Fax: (801) 581-7532
801-581-2000
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor (Clinical) |
| Academic Divisions | Oncology |
Academic Locations
Huntsman Cancer Institute
801-585-0255
(801) 585-0124
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor (Clinical) |
| Academic Divisions | Oncology |
Education History
| Fellowship | University of Utah School of Medicine Hematology/Oncology Fellow, 2021 |
| Residency | University of Utah School of Medicine Internal Medicine Resident, 2019 |
| Professional Medical | University of Minnesota Medical School Medicine M.D., 2016 |
| Undergraduate | Luther College Biology B.A., 2011 |
| Graduate Training | University of Utah School of Medicine Clinical Investigation M.S., |
Selected Publications - Journal Articles
Journal Article
- Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol, 17(2), 108-123.
- Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I (2019). Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open, 4(4), e000539.
- Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I (2018). Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 3(5), e000386.
- Nevala-Plagemann C, Lee C, Tolar J (2015). Placenta-based therapies for the treatment of epidermolysis bullosa. Cytotherapy, 17(6), 786-795.
Case Report
- Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol, 4.
- Nevala-Plagemann C, Powers P, Mir-Kasimov M, Rose R (2019). A Fatal Case of Septic Shock Secondary to Acinetobacter Bacteremia Acquired from a Platelet Transfusion. Case Rep Med, 2019, 3136493.